Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06765187 · ClinicalTrials.gov registry record
A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire
A clinical trial, sponsored by Sanofi.
- Completed
- Registry status
- 1,007
- Enrollment target
NCT06765187 is a clinical trial that has completed, run by Sanofi. The registered enrollment target is 1,007 participants.
The verdict
NCT06765187 has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- 1,007 participants
- Enrollment target
Study Summary
This study aims to assess patient-reported experiences following trivalent recombinant influenza vaccine (RIV3) vaccination using the Vaccinees' Perception of Injection (VAPI) questionnaire, identify factors related to vaccine choice and future vaccination intentions in each case, and assess the cross-validity of VAPI, by establishing magnitude of correlations to EuroQol 5 Dimensions, 5 Levels (EQ-5D-5L) domains. Participants will need approximately 30 minutes to complete the self-administered online survey. Individuals will be recruited via a U.S. retail chain partner that offers the RIV3 vaccine as part of their routine influenza vaccination program
Interventions
- BIOLOGICAL Trivalent Recombinant Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,007 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2025-12-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06765187
The ClinicalTrials.gov registry entry for NCT06765187 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,007 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Trivalent Recombinant Influenza Vaccine is the first listed.
NCT06765187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06765187 about?
NCT06765187 is a clinical study titled "A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire". This study aims to assess patient-reported experiences following trivalent recombinant influenza vaccine (RIV3) vaccination using the Vaccinees' Perception of Injection (VAPI) questionnaire, identify factors related to vaccine choice and future vaccination intentions in each case, and assess the cro...
What is the current status of trial NCT06765187?
This trial is currently completed. The enrollment target is 1,007 participants. The study started on 2024-11-18. Estimated completion is 2025-12-22.
What interventions are being tested in trial NCT06765187?
The interventions under investigation include: Trivalent Recombinant Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06765187?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.